Login / Signup

T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Geling LiEmily WaiteJulie Anna Wolfson
Published in: Blood advances (2017)
A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 JAK3-activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).
Keyphrases
  • rheumatoid arthritis
  • case report
  • acute myeloid leukemia
  • bone marrow
  • early onset
  • young adults
  • mental health
  • ulcerative colitis
  • signaling pathway
  • locally advanced
  • radiation therapy
  • childhood cancer